

Department of Psychiatry and Neurosciences

USF Health · College of Medicine

Office of the Chair - Week of October 4 – 8, 2010

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Meetings

Tuesday 10/05/10 12:00 noon Outpatient Clinic Committee Meeting

Thursday 10/07/10 8:00 a.m. Call Center Meeting

Resident Lectures:

8:00 a.m. PGY-1, PGY-2, PGY-3, PGY-4, CHILD, GERI "PRITE"

9:00 a.m. PGY-1, PGY-2, PGY-3, PGY-4, CHILD, GERI "PRITE"

10:00 a.m. PGY-1, PGY-2, PGY-3, PGY-4, CHILD, GERI "PRITE"

12:00 noon NO GRAND ROUNDS

Friday 10/08/10

Medical Student Lectures

8:00 a.m. "Psychiatric Emergencies" Dr. Sandra Stock

9:00 a.m. "Psychopharmacology" Dr. Glenn Catalano

11:00 a.m. "Mood Disorders" Dr. Barbara Lubrano

1:30 p.m. "Neurological Emergencies" Dr. Rossitza Chichkova

In The Know

Happy Birthday wishes to Pat Crump/October 7th.

On October 8, 2010 from 7:00 – 10:00 p.m., The Carter-Jenkins Center will present "Reel to Real - Departures (original title Ukuribito, 2008)". The session will be directed by Frances Marton MSW, Associate Director of The Carter-Jenkins Center.

Research Happenings!

Research News Updates:

As basic research is expanding in the Department of Psychiatry & Neurosciences, information in this newsletter will now include monthly updates on research happenings from:

- the Sam & Geri Rashid Laboratory for Developmental Neurobiology in the Archie and Mary-Louise Silver Child Development Center (SCDC) - Dr. Jun Tan
- the Laboratory of Neuropsychopharmacology - Dr. Lynn Wecker
- the Laboratory of Neuroimmunology - Dr. Brian Giunta
- the Roskamp Laboratory - Dr. Francisco Fernandez
- our K30 Scholar - Dr. Jamie Winderbaum Fernandez

This month's updates include:

Manuscripts in press or recently published

- E. Carla Parker-Athill and Jun Tan (2010) Maternal Immune Activation and Autism Spectrum Disorder: Interleukin-6 Signaling as a Key Mechanistic Pathway, Neurosignals, in press.
- Jamie Winderbaum Fernandez, Kavon Rezai-Zadeh, Demian Obregon, and Jun Tan (2010) EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP. FEBS Letters, in press.
- Wecker, L., Pollock, V.V., Pacheco, M.A. and Pastoor, T. (2010) Nicotine-induced Up Regulation of $\alpha 4\beta 2$ Neuronal Nicotinic Receptors Is Mediated by the PKC-dependent Phosphorylation of $\alpha 4$ Subunits, Neurosci., in press; online at <http://dx.doi.org/10.1016/j.neuroscience.2010.09.005>.

New Grants

- Jun Tan (P.I.) IL-6-mediated Jak2/Stat3 signaling and Brain Development, 1R21MH087849-01A1, 09/01/2010 - 06/30/2012

Personnel Happenings

- Gabriel de Erausquin, MD, PhD, will be joining the Department as the Bob and Diane Roskamp Chair in Biological Psychiatry. Dr. de Erausquin is a neurologist/psychiatrist with training in neurobiology and a master's degree in epidemiology and genetics who is currently funded to study the genetic control of the relationship between parkinsonism and schizophrenia. Clinically, he will be leading an interdisciplinary effort between Psychiatry, Neurology and Neurosurgery in neurostimulation. He will be working closely with Drs. Marsh and Upshaw in the expansion of rTMS to neurobehavioral disorders.
- Dr. Min Song from the University of Illinois Medical School will be joining the Sam & Geri Rashid Laboratory for Developmental Neurobiology as a postdoctoral research fellow.
- Mr. Jared Ehrhart, graduate student in the Department of Molecular Pharmacology and Physiology studying under the tutelage of Dr. Tan, will be defending his Ph.D. dissertation on October 25, 2010.
- Dr. Lynn Wecker presented a seminar entitled "Role of PKA and PKC in the Nicotine-Induced Up Regulation of $\alpha 4\beta 2$ Nicotinic Receptors" in the Department of Pharmacology and Toxicology at the East Carolina University Brody School of Medicine in Greenville, NC on September 1, 2010.

Research Facts

Did you know... the Department has a new Research web page – see <http://health.usf.edu/medicine/psychiatry/research/index.htm>

What else didn't you know :

1. >50% of all new patients seen in our outpatient clinic want information on research being done in our department.
2. Participants in clinical trials receive psychiatric evaluations and follow-up visits; study specific testing (psychiatric, cognitive, behavioral, and health outcomes); labs; ECGs; physical exams; study medication; transportation assistance; 24/7 access to research team, a small stipend; and in some studies, medication vouchers for concomitant medications – all at NO COST.
3. The Department has a new Research web page - see <http://health.usf.edu/medicine/psychiatry/research/index.htm>

What else didn't you know:

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Abilify IM Depot Study

The Aripiprazole IM Depot Study extension has been extended! Participants in this study can now continue to receive **open-label Aripiprazole IM Depot until it is FDA approved up to a maximum of 8 years**. Our site can enroll up to **40 6 additional subjects in this study until October**. Participants are started on oral Abilify – once tolerability is determined, the participant is switched to Aripiprazole IM Depot. Aripiprazole IM Depot is administered monthly. All study related medications, labs, ECGs and study visits are at no charge to participants throughout the duration of the extension study (remember up to 8 years or until drug is FDA approved). Principal Investigator – Carlos Santana, M.D.

Cognitive Deficits in Schizophrenia

We are participating in a nationwide clinical research trial evaluating the safety and efficacy of an investigational medication used in the treatment of **Cognitive Deficits in Schizophrenia**. This is a 12 week '**ad on medication**' study for individuals with schizophrenia between the ages of 20-55. To be eligible subjects must have been *diagnosed or treated* for at least 2 years prior to screening and be stable on 1-2 atypical antipsychotic medications. Principal Investigator - Carlos Santana, M.D.

Bipolar I Disorder, Manic or Mixed

This is a nationwide clinical research study evaluating the safety and tolerability of Cariprazine (an investigational medication) in patients with **Bipolar I Disorder**. The study is a **20-week open-label study**. Patients must be 18-65 years of age and be willing to be hospitalized during the initial titration phase of the study. Principal Investigator – Patrick Marsh, M.D.

Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as **adjunctive therapy** in patients with **major depression associated with Bipolar I Disorder**. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator – Carlos Santana, M.D.

Schizophrenia 'Jail Recidivism' Study

We are one of 40 sites in the United States participating site for this landmark study looking at arrest recidivism in adults with Schizophrenia. The study is a **15-month open-label study** comparing the rate of arrest recidivism and other health outcome measures in patients receiving **oral antipsychotic treatment compared to paliperidone palmitate injections**. Participants receive antipsychotic medications and study visits at no charge throughout the study. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 60 days prior to screening to be eligible to participate.

Principal Investigator – Brian Keefe, M.D.